298 - The implementation of randomized trials in the treatment of advanced ovarian cancer with HIPEC: waiting for new evidence.
298 - The implementation of randomized trials in the treatment of advanced ovarian cancer with HIPEC: waiting for new evidence.
J Cancer Res Ther 2013, 1(1): 60–61
Coccolini F, Lotti M, Catena F , Pisano M , Grosso G , Frigerio L and Ansaloni L
Ovarian cancer (OC) is one of the most frequent mortality causes among female neoplasms. A lot of data is available on the efficiency and the relative safety of the different treatments. In the last twenty years the overall survival (OS) and the disease free survival (DFS) have enormously incremented thanks to the combined chemotherapy regimens and the incredible progresses of surgery. These progresses are also related to the increased ability in managing patients more and more compromised, i.e. older and weaker. In addition to that, more than twenty years ago, Sugarbaker et al. started to treat the peritoneal cancer diffusion as a loco-regional disease. This change of practice has been demonstrated to be a real revolution by following studies.
